Trials / Available
AvailableNCT05346835
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Janssen Scientific Affairs, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilta-cel OOS Therapy | Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion. |
Timeline
- First posted
- 2022-04-26
- Last updated
- 2026-02-13
Locations
138 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT05346835. Inclusion in this directory is not an endorsement.